<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03604276</url>
  </required_header>
  <id_info>
    <org_study_id>1100316-599</org_study_id>
    <nct_id>NCT03604276</nct_id>
  </id_info>
  <brief_title>Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage</brief_title>
  <acronym>HASH4-CSF</acronym>
  <official_title>Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage (HASH4-CSF) - An Observational Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MaineHealth</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MaineHealth</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the relationship between the Neuroinflammatory&#xD;
      response and headache pain after subarachnoid hemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent headache is a significant medical issue that affects 20% of patients who survive&#xD;
      an aneurysmal subarachnoid hemorrhage (SAH). This headache may last years, severely affecting&#xD;
      quality of life. Laboratory evidence suggests that the persistent headache may be a result of&#xD;
      a maladaptive neuroinflammatory response to the hemorrhage injury that is more vigorous than&#xD;
      necessary. The goal of this study is to measure key immunomodulators in the blood and the&#xD;
      cerebrospinal fluid of these patients in order to determine the magnitude and dynamics of&#xD;
      their neuroinflammatory response. In addition, the investigators will collect and analyze&#xD;
      observational data about the success of medications to treat headache, with a specific focus&#xD;
      on the anti-inflammatory agent dexamethasone, in managing acute headache pain and preventing&#xD;
      the development of persistent headaches in patients after SAH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of the neuroinflammatory response in the CSF and blood of patients with non-traumatic SAH.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of correlation between the neuroinflammatory response and severity/presence of headache pain.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of correlation between the neuroinflammatory response and development of chronic headache.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the neuroinflammatory response in the CSF and blood in patients treated with dexamethasone versus other analgesics post SAH.</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of dexamethasone versus other analgesics in their ability to improve measures of quality of life.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <condition>Headache</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Eligible patients are patients with a non-traumatic subarachnoid hemorrhage who are treated&#xD;
        with an external ventricular drain for symptomatic hydrocephalus.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-traumatic subarachnoid hemorrhage&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Treated with external ventricular drainage&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Traumatic SAH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth K Glisic, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MaineHealth</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Eldridge, BSN, RN</last_name>
    <phone>207-662-3231</phone>
    <email>eldria@mmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Lord, BSN, RN-BC</last_name>
    <phone>207-662-5206</phone>
    <email>lordc@mmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Eldridge, BSN, RN</last_name>
      <phone>207-662-3231</phone>
      <email>eldria@mmc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MaineHealth</investigator_affiliation>
    <investigator_full_name>Elizabeth Glisic</investigator_full_name>
    <investigator_title>Clinical Pharmacist</investigator_title>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Subarachnoid hemorrhage</keyword>
  <keyword>Neuroinflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

